Article

First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL

2015-12-03

Abstract excerpt

Abstract Chimeric antigen receptor (CAR)19 T-cells exhibit powerful anti-leukemic effects in patients with B cell malignancies. However, the complexity of production of patient bespoke T cell products is a major barrier to the broader application of this approach. We are investigating a novel strategy to enable "off-the-shelf"' therapy with mismatched donor CAR19 T cells. Transcription activator-like effector nucl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f7c2d729-69c0-560d-83cc-10ded3d14eb7
DOI: 10.1182/blood.v126.23.2046.2046

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALLDOI 10.1182/blood.v126.23.2046.2046Read

CAR therapy: the CD19 paradigmSemantic proximity Read

Preferential disruption of HLA-A/B enhances allogeneic CAR-T cell expansion and antitumor capacity in B cell malignanciesSemantic proximity Read

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemiaSemantic proximity Read

CD62L-selected umbilical cord blood universal CAR T cellsSemantic proximity Read

Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome.Semantic proximity Read

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALLSemantic proximity Read

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCRSemantic proximity Read

Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphomaSemantic proximity Read

Tvt CAR7: Phase 1 Clinical Trial of Base-Edited "Universal” CAR7 T Cells for Paediatric Relapsed/Refractory T-ALLSemantic proximity Read

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialSemantic proximity Read

Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell ImmunotherapiesSemantic proximity Read

Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic EffectsSemantic proximity Read